Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Shionogi to acquire IntraBio in deal worth $2bn
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Alexion and Aide Health launch app for people with rare diseases
More than 3.5 million people in the UK live with a rare condition
MAD World Summit 2026 secures official accreditation from The CPD Group
MAD World Summit takes place in London on 26 November at Convene, 155 Bishopsgate
Latest content
Avalere Health appoints Wendy Jory as Senior Vice President, Market Access
Jory was most recently Medicine Commercialization Lead, Product and Portfolio Strategy at GSK
Read More
Beam Therapeutics appoints Eric Foster as Chief Commercial Officer
Foster previously held senior roles at Ardelyx, Amgen, Horizon and GlaxoSmithKline
Read More
Nuclera appoints Carl Raimond as CEO
Co-founder and former CEO Michael Chen transitions to Chief Scientific and Business Officer
Read More
Inizio Evoke appoints Barbara Patchefsky as Global Client Lead
Patchefsky most recently served as Global Client Director at Havas Health & You
Read More
Intelligence
Who’s steering? Why pharma needs humans at the helm of AI
Understanding how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms
Read More
The impact of AI and digital health on chronic diseases
Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?
Read More
Regulatory complexity: the challenges of navigating the new normal
How functional service provider models are helping pharma adapt to regulatory uncertainty
Read More
From ambition to action: realising the true value of health
Why industry needs to engage earlier, explain value more clearly, understand service pressures and take shared responsibility for implementation
Read More
Strengthening engagement with HCPs needs deep understanding not digital bombardment
Closing the critical gap between HCPs’ need for information and the pharma industry’s ability to deliver relevant, tailored content
Read More
Cell and gene therapies – moving from niche innovations towards broader clinical use
Looking at the regulatory challenges of cell and gene therapies for serious or life-threatening rare diseases
Read More
Blogs
Latest
INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar
October 26, 2026 | Uniphar|Ebstrocel™, Expanded access, INmune Bio, Market Access, Uniphar
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization
Redefining Pediatric Epilepsy Care: Why We Must Move Beyond Symptom Suppression
October 21, 2026 | Medscape Education|#WomenInMedicine #Pediatrics #EpilepsyWarrior #HearFromHer
For families navigating pediatric epilepsy, the condition dictates every moment of their lives. The constant, crippling “anticipatory anxiety” of when the next seizure might hit …
ANTHEM strengthens team with three appointments following Healthy Influence launch
October 19, 2026 | Resonant Group|
Healthcare communications consultancy welcomes new talent as it invests in its next phase of growth
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
October 14, 2026 | Genesis Research Group|HEOR, Market Access, Orphan Drugs, Payers, access and pricing, payer engagement, payer research, rpr
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new …
What 90 Minutes of Live AI Case Practice Revealed About Physician Readiness
October 12, 2026 | Medscape Education|
At EHA 2026 in Stockholm, 425 hematologists and oncologists attended an independent, 90-minute Medscape symposium on the practical and ethical use of AI. The format …
Going private: what our year taught me about the patients pharma hasn’t yet spotted
October 26, 2026 | 11 London|
A thought piece on the rise of private healthcare, and why brands should help new kinds of patients and HCPs
What the Most Favored Nation (MFN) policy means for UK Pharma
October 20, 2026 | Amiculum|
By Jed Avissar and Manca Povsic
Your AI pilot works. That’s the problem.
October 14, 2026 | 11 London|Data Strategy
What breaks when you scale it won’t be the model. It’ll be your data.
“We’ve been told we can’t touch AI”
October 14, 2026 | 11 London|
It’s not been a great few weeks for anyone trying to make the calm, sensible case for AI tools. Researchers have been quitting the big …
Pharma leadership strategies for talent, AI adoption, and continuous learning
October 8, 2026 | Inizio|AI, Digital, Pharma, healthcare
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to …